動脈粥狀硬化藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按診斷、按治療、按給藥途徑、按最終用戶、按地區和競爭進行細分，2020-2030 年預測

2024 年全球動脈粥狀硬化藥物市場價值為 188.5 億美元，預計到 2030 年將達到 228.4 億美元，預測期內的年複合成長率(CAGR) 為 3.21%。動脈粥狀硬化是一種因脂肪斑塊堆積而導致動脈變窄和硬化的疾病，它仍然是全球重大的健康問題。它是心臟病、中風和其他心血管併發症的主要原因，每年導致數百萬人死亡。隨著動脈粥狀硬化盛行率的不斷上升，動脈粥狀硬化藥物市場也出現了大幅成長。

不良飲食、缺乏運動和吸煙等不健康的生活方式因素是導致全球動脈粥狀硬化發病率上升的主要原因，導致大量患者需要治療。此外，全球人口老化風險更高，預計將推動對動脈粥狀硬化藥物的需求。醫療技術和診斷技術的進步使得更早發現成為可能，有助於更及時地介入和治療。公共衛生運動和人們對心血管健康的認知不斷提高也鼓勵了更多的人尋求治療。

全球動脈粥狀硬化藥物市場雖然有重大機會，但也面臨挑戰。隨著動脈粥狀硬化負擔的不斷加重，持續的創新和研究對於開發有效的治療方法至關重要。個人化醫療和針對性治療可望改善患者的治療效果。然而，必須解決與藥品定價、患者依從性和日益激烈的競爭相關的挑戰，以確保有需要的人能夠獲得藥物。製藥公司、醫療保健提供者和政策制定者之間的合作對於對抗動脈粥狀硬化及其對全球健康的影響至關重要。

主要市場促進因素

動脈粥狀硬化盛行率上升

主要市場挑戰

競爭加劇

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球動脈粥狀硬化藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依診斷（踝臂指數、多普勒超音波、超音波心臟檢查、心電圖、血液檢查、其他）
  • 依治療方法（藥物、手術、其他）
  • 依給藥途徑（口服、腸胃外、其他）
  • 按最終使用者（醫院和診所、門診護理中心、其他）、按地區
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美動脈粥狀硬化藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲動脈粥狀硬化藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太動脈粥狀硬化藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美動脈粥狀硬化藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲動脈粥狀硬化藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi SA
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

第 15 章：策略建議

第16章 關於出版商,免責事項

The Global Atherosclerosis Drugs Market was valued at USD 18.85 billion in 2024 and is projected to reach USD 22.84 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.21% during the forecast period. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to fatty plaque accumulation, continues to be a significant global health issue. It is a leading cause of heart disease, stroke, and other cardiovascular complications, resulting in millions of deaths annually. The market for atherosclerosis drugs has seen substantial growth, driven by the increasing prevalence of this condition.

Unhealthy lifestyle factors such as poor diet, physical inactivity, and smoking are major contributors to the rising incidence of atherosclerosis worldwide, leading to a large patient population in need of treatment. Furthermore, the aging global population is at higher risk, which is expected to drive demand for atherosclerosis medications. Advances in medical technology and diagnostics have enabled earlier detection, facilitating more timely interventions and treatments. Public health campaigns and increasing awareness about cardiovascular health have also encouraged more individuals to seek treatment.

While the Global Atherosclerosis Drugs Market presents significant opportunities, it also faces challenges. With the rising burden of atherosclerosis, ongoing innovation and research are critical to developing effective therapies. Personalized medicine and targeted treatments show promise in improving patient outcomes. However, challenges related to drug pricing, patient adherence, and growing competition must be addressed to ensure accessibility for those in need. The collaboration between pharmaceutical companies, healthcare providers, and policymakers will be essential to combating atherosclerosis and its impact on global health.

Key Market Drivers

Rising Prevalence of Atherosclerosis

Atherosclerosis, characterized by plaque buildup in arteries, is becoming more widespread worldwide. This condition significantly increases the risk of heart attacks, strokes, and other cardiovascular diseases, making it a global healthcare priority. As modern lifestyles contribute to obesity, hypertension, and high cholesterol, the need for effective treatments for atherosclerosis is intensifying. Diets high in saturated fats, trans fats, and processed foods, common in many regions, further exacerbate the risk factors. Additionally, atherosclerosis is more prevalent in older individuals, and as the global population ages, the incidence of this condition is expected to rise, further stressing healthcare systems. Tobacco use and diabetes are also major contributors to the increasing prevalence of atherosclerosis.

Recent research has uncovered cancer-like features in atherosclerosis, highlighting potential new treatment avenues. Studies supported by the National Institutes of Health (NIH) suggest that smooth muscle cells in arteries may take on characteristics similar to cancer cells, worsening the condition. This discovery opens the door for novel therapies, such as using anti-cancer drugs to target these tumor-like processes, offering hope for more effective treatments.

Key Market Challenges

Increasing Competition

The atherosclerosis drugs market is highly competitive, with numerous established pharmaceutical companies and emerging players vying for market share. Major pharmaceutical companies like Pfizer, AstraZeneca, and Merck have dominated the market for years, benefiting from blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin). However, newer entrants are introducing innovative therapies and specialized drug formulations targeting different aspects of atherosclerosis treatment. These companies are focusing on niche areas such as LDL cholesterol reduction or inflammation to address unmet needs in the market.

The rise of biosimilars and generics has further intensified competition, as these cost-effective alternatives to branded drugs become more prevalent. Smaller companies or startups face challenges related to regulatory approvals, clinical trials, and securing adequate funding. The dominance of established market leaders adds to the difficulty for newcomers to differentiate themselves. To remain competitive, companies must focus on innovation, whether through new drug formulations, strategic partnerships, or acquisitions.

Key Market Trends

Technological Advancements

Technological progress in healthcare is revolutionizing the development, diagnosis, and treatment of atherosclerosis, which is contributing to the growth of the market. Modern imaging technologies such as CT angiography, MRI, and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, enabling more accurate assessment of plaque buildup and its severity. Additionally, blood tests that incorporate biomarkers like high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) aid in the early detection and risk assessment of atherosclerosis.

Artificial intelligence (AI) and machine learning are also enhancing the diagnosis of atherosclerosis by analyzing medical imaging and patient data to identify patterns and predict disease progression. These advancements are improving both the accuracy and efficiency of diagnosing atherosclerosis, contributing to better patient outcomes.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi S.A.
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

Report Scope

This report segments the Global Atherosclerosis Drugs Market into the following categories:

• Diagnosis
• Ankle-brachial Index
• Doppler Ultrasound
• Echocardiogram
• Electrocardiogram
• Blood Tests
• Others
• Treatment
• Medication
• Surgery
• Others
• Route of Administration
• Oral
• Parenteral
• Others
• End User
• Hospitals & Clinics
• Ambulatory Care Centers
• Others
• Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

The report includes detailed profiles of major companies in the atherosclerosis drugs market, offering insights into their market strategies and financial performance.

Available Customizations

The Global Atherosclerosis Drugs Market report can be customized to meet specific company needs, including detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atherosclerosis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
  • 5.2.2. By Treatment (Medication, Surgery, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others),By Region
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Atherosclerosis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atherosclerosis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Atherosclerosis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Atherosclerosis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Atherosclerosis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atherosclerosis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Atherosclerosis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Atherosclerosis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. France Atherosclerosis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Atherosclerosis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia-Pacific Atherosclerosis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Atherosclerosis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Atherosclerosis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Atherosclerosis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Atherosclerosis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Atherosclerosis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. South America Atherosclerosis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Atherosclerosis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Atherosclerosis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Atherosclerosis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. Middle East and Africa Atherosclerosis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Atherosclerosis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Atherosclerosis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Atherosclerosis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Merck & Co. Inc.
• 14.4. Pfizer Inc.
• 14.5. Eli Lilly and Co.
• 14.6. Sanofi S.A.
• 14.7. AstraZeneca Plc
• 14.8. Bayer AG
• 14.9. Regeneron Pharmaceuticals Inc.
• 14.10. GSK Plc

15. Strategic Recommendations

16. About Us & Disclaimer